ProCE Banner Activity

Combination Therapy With BRAF Inhibitors: A New Frontier in BRAF-Mutant CRC

Clinical Thought
BRAF-mutated CRC has a poor prognosis and limited treatment options. Read my thoughts on how combinations with BRAF inhibitors are offering promising benefits for this challenging population.

Released: August 14, 2017

Expiration: August 13, 2018

No longer available for credit.

Share

Faculty

E. Scott Kopetz

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer Healthcare Pharma

Genentech TEXT Only

Lilly

Taiho Pharmaceuticals

Faculty Disclosure

Primary Author

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Scott Kopetz, MD, PhD, FACP, has disclosed that he has received consulting fees from Amgen, Array, Bayer, Genentech, MolecularMatch, and Taiho.